Posted by Michael Wonder on 07 Jun 2018
ICER's final report on CFTR modulators for cystic fibrosis calls for manufacturer restraint and increased transparency in pricing decisions
7 June 2018 - Pricing overreach harms people with cystic fibrosis and threatens the health care system's ability to support future innovation.
The ICER today released a final evidence report and report-at-a-glance on cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The report includes combination therapies tezacaftor/ivacaftor (Symdeko, Vertex Pharmaceuticals) and lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), and monotherapy ivacaftor (Kalydeco, Vertex Pharmaceuticals), for the treatment of cystic fibrosis.
ICER's analysis was reviewed at a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), where a majority of the Council voted that, in their specified indications, Kalydeco, Orkambi, and Symdeko in combination with best supportive care all offer a net health benefit compared to best supportive care alone.
